Segment Information (Tables)

6 Months Ended

Jun. 27, 2025

Segment Reporting [Abstract]

Segment Results

Detailed segment data for the three and six-month periods ended June 27, 2025 and June 28, 2024 is as follows ($ in millions):

	Biotechnology		Life Sciences		Diagnostics		Other(a)		Total
For the Three-Month Period Ended June 27, 2025:
Sales	$	1,850	$	1,777	$	2,309	$	—	$	5,936
Less:
Depreciation	(38)		(45)		(100)		(2)		(185)
Amortization of intangible assets	(228)		(150)		(48)		—		(426)
Impairments(b)	—		(432)		—		—		(432)
Other segment expenses(c)	(1,053)		(1,389)		(1,607)		(84)		(4,133)
Operating profit (loss)	$	531	$	(239)	$	554	$	(86)	$	760
For the Three-Month Period Ended June 28, 2024:
Sales	$	1,713	$	1,770	$	2,260	$	—	$	5,743
Less:
Depreciation	(35)		(41)		(100)		(2)		(178)
Amortization of intangible assets	(214)		(140)		(48)		—		(402)
Other segment expenses(c)	(1,002)		(1,356)		(1,556)		(81)		(3,995)
Operating profit (loss)	$	462	$	233	$	556	$	(83)	$	1,168

	Biotechnology		Life Sciences		Diagnostics		Other(a)		Total
For the Six-Month Period Ended June 27, 2025:
Sales	$	3,462	$	3,457	$	4,758	$	—	$	11,677
Less:
Depreciation	(72)		(90)		(200)		(4)		(366)
Amortization of intangible assets	(441)		(299)		(96)		—		(836)
Impairments(b)	(15)		(432)		—		—		(447)
Other segment expenses(c)	(1,962)		(2,674)		(3,190)		(168)		(7,994)
Operating profit (loss)	$	972	$	(38)	$	1,272	$	(172)	$	2,034
For the Six-Month Period Ended June 28, 2024:
Sales	$	3,237	$	3,515	$	4,787	$	—	$	11,539
Less:
Depreciation	(77)		(79)		(197)		(4)		(357)
Amortization of intangible assets	(432)		(281)		(96)		—		(809)
Other segment expenses(c)	(1,941)		(2,687)		(3,108)		(157)		(7,893)
Operating profit (loss)	$	787	$	468	$	1,386	$	(161)	$	2,480

(a) Other consists of unallocated corporate costs and other costs not considered part of management’s evaluation of reportable segment operating performance.

(b) For information on the impairments, refer to Note 8.

(c) Other segment expenses for each reportable segment include cost of sales, selling, general and administrative (“SG&A”) expenses and research and development (“R&D”) expenses, excluding in each case depreciation, amortization of intangible assets and impairments. Included within these categories of expenses are overhead expenses, stock compensation expense, restructuring charges and allocated corporate expenses.

The following table presents identifiable assets as of June 27, 2025 and December 31, 2024 ($ in millions):

	June 27, 2025		December 31, 2024
Identifiable assets:
Biotechnology	$	37,562	$	34,605
Life Sciences	23,397		23,211
Diagnostics	14,537		14,204
Other	6,124		5,522
Total	$	81,620	$	77,542

The following table presents capital expenditures for the three and six-month periods ended June 27, 2025 and June 28, 2024 ($ in millions):

	Three-Month Period Ended				Six-Month Period Ended
	June 27, 2025		June 28, 2024		June 27, 2025		June 28, 2024
Capital expenditures:
Biotechnology	$	80	$	111	$	161	$	213
Life Sciences	41		50		89		110
Diagnostics	125		126		240		253
Other	2		—		3		2
Total	$	248	$	287	$	493	$	578